NCT00094796View on ClinicalTrials.gov

Rosiglitazone to Reverse Metabolic Defects in Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 20, 2004

Study Completion Date

September 3, 2008

Conditions
Diabetes Mellitus, Type IIInsulin Resistance
Interventions
PROCEDURE

Exercise cardiopulmonary metabolic testing

PROCEDURE

Skeletal muscle biopsy

PROCEDURE

Brachial artery reactivity testing

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Unknown

Medical College of Virginia, Richmond

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00094796 - Rosiglitazone to Reverse Metabolic Defects in Diabetes | Biotech Hunter | Biotech Hunter